Neuren Pharmaceuticals Limited (OTCMKTS:NURPF – Get Free Report)’s share price traded down 4.5% during mid-day trading on Tuesday . The stock traded as low as C$8.48 and last traded at C$8.48. 446 shares were traded during mid-day trading, a decline of 51% from the average daily volume of 918 shares. The stock had previously closed at C$8.88.
Neuren Pharmaceuticals Trading Up 2.5%
The firm’s fifty day moving average is C$8.79 and its 200 day moving average is C$10.09.
About Neuren Pharmaceuticals
Neuren Pharmaceuticals (OTCMKTS:NURPF) is an Australian-based clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for the treatment of neurodevelopmental and neurodegenerative disorders. The company’s research efforts center on addressing unmet medical needs in conditions such as Rett syndrome, Fragile X syndrome and Angelman syndrome. Neuren is publicly traded on the Australian Securities Exchange and maintains an over-the-counter listing in the United States, reflecting its commitment to global capital markets and investor engagement.
The company’s lead candidate, trofinetide (NNZ-2566), is a synthetic analogue of a naturally occurring peptide that has been evaluated in late-stage clinical trials for Rett syndrome and Fragile X syndrome.
Recommended Stories
- Five stocks we like better than Neuren Pharmaceuticals
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
